Bio-Rad Laboratories, Inc. (BIO.B)

NYSE: BIO.B · USD

$380

+0.00 (0.0%)· Recorded snapshot

Market cap	10.2B
Revenue (ttm)	2.6B
Net income (ttm)	222.4M
EPS (ttm)	$8.26
Shares out	26.7M
P/E (trailing)	46.0x
P/E (forward)	41.8x
Volume	1
Beta	1.07

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2.6B
Net income (ttm): 222.4M
EPS (ttm): $8.26
P/E (trailing): 46.0x
P/E (forward): 41.8x
Market cap: 10.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E41.8

P25 n/aP50 n/aP75 n/a

Trailing P/E46

P25 n/aP50 n/aP75 n/a

ROE3.1

P25 n/aP50 n/aP75 n/a

ROIC2.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BIO.B indicators

Market & fundamental data

Available fields

257

Groups with data

Currency

USD

Showing 257 of 257 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000012208
Company name	Bio-Rad Laboratories, Inc.
Country	United States
Country code	US
CUSIP number	090572108
Earnings date	2026-11-04
Earnings time	amc
Employees	7,450
Employees change	-250
Employees growth	-3.25%
Enterprise value	$9.9B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1952
Industry	Medical Devices
Is primary listing	No
Is SPAC	No
ISIN number	US0905721082
Last 10-K release date	2026-02-13
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split date	2002-03-08
Last stock split type	Forward
Market cap	$10.2B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	No
Price	$379.50
Price currency	USD
Sector	Healthcare
SIC code	3826
Stock price date	2026-10-28
Symbol	BIO.B
U.S. state	California
Website	https://www.bio-rad.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	40.89x
Average P/E ratio (10Y)	65.26x
Earnings yield	2.18%
EV/Earnings	44.66x
EV/EBIT	36.47x
EV/EBITDA	22.52x
EV/FCF	28.13x
EV/Sales	3.84x
FCF / EV yield	3.56%
FCF yield	3.47%
Forward EV/Sales	3.78x
Forward P/E	41.78x
Forward P/S	3.87x
Graham number	223.36975
Graham upside	-41.14%
Industry forward P/E	19.81x
Industry P/E	39.28x
Lynch fair value	$41.46
Lynch upside	-89.08%
P/(FCF - SBC) ratio	34.77x
P/(OCF - SBC) ratio	23.55x
P/B ratio	1.42x
P/E ratio	45.97x
P/FCF ratio	28.83x
P/OCF ratio	20.66x
P/S ratio	3.93x
Price / tangible book value	1.58x
Price/EBITDA ratio	23.08x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	10.52%
EBITDA margin	17.03%
Effective tax rate	36.53%
FCF margin	13.64%
Gross margin	52.04%
Operating margin	10.52%
Pretax margin	13.53%
Profit margin	8.59%
Profit per employee	$29,852
Revenue per employee	$347,557
ROA	1.66%
ROA (5Y)	1.87%
ROCE	2.93%
ROE	3.11%
ROE (5Y)	-3.05%
ROIC	2.54%
ROIC (5Y)	3.87%
SBC / revenue	2.33%
Tax / revenue	4.94%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-28.17%
EPS growth (Q)	18.68%
EPS growth 10Y	9.61%
EPS growth 5Y	-42.73%
FCF growth	-4.83%
FCF growth (Q)	-5.79%
FCF growth (QoQ)	-14.6%
FCF growth 3Y	31.84%
FCF growth 5Y	-9.65%
Gross profit growth	-1.12%
Gross profit growth (Q)	0.14%
Gross profit growth 3Y	-3.42%
Gross profit growth 5Y	-3.73%
Net income growth	-30.33%
Net income growth (Q)	16.87%
Net income growth 5Y	-44.02%
OCF growth	-7.79%
OCF growth (Q)	-15.28%
OCF growth (QoQ)	-8.7%
OCF growth 10Y	10.12%
OCF growth 3Y	19.76%
OCF growth 5Y	-6.48%
Operating income growth	14.36%
Operating income growth (Q)	-5.7%
Operating income growth 3Y	-9.66%
Operating income growth 5Y	-11.79%
Revenue growth	1.37%
Revenue growth (Q)	-0.09%
Revenue growth (QoQ)	9.95%
Revenue growth 10Y	2.47%
Revenue growth 3Y	-2.21%
Revenue growth 5Y	-2.1%

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-139.5M
Depreciation and amortization	$168.7M
EBIT	$272.3M
EBITDA	$441M
EPS	$8.26
FCF per share	$13.21
Financing cash flow	$-120.8M
Free cash flow	$353.1M
Free cash flow minus SBC	$292.8M
Gross profit	$1.3B
Income taxes	$128M
Investing cash flow	$-237.1M
Net borrowing	$-500,000
Net cash flow	$147.1M
Net income	$222.4M
Operating cash flow minus SBC	$432.3M
Operating income	$272.3M
Revenue	$2.6B
Stock-based compensation	$60.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.19
Book value per share	$268.30
Debt / EBITDA	2.69
Debt / equity	0.19
Debt / FCF	3.88
Goodwill	$574.3M
Interest coverage	5.58
Long-term assets	$7.2B
Long-term liabilities	$2.1B
Net cash (debt)	$248.1M
Net cash / market cap	2.44%
Net debt / EBITDA	-0.56
Net debt / equity	-0.03
Net debt / FCF	-0.7
Piotroski F-Score	5
Property, plant and equipment	$671.9M
Shareholders' equity	$7.2B
Tangible book value	$6.4B
Tangible book value per share	$240.84
Total assets	$10.3B
Total cash	$1.6B
Total debt	$1.4B
Total liabilities	$3.1B
WACC	9.19%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.25
Current assets	$3B
Current liabilities	$961.3M
Current ratio	3.14
Inventory turnover	1.57
Net working capital	$875M
Quick ratio	2.15
Working capital	$2.1B
Working capital turnover	1.2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	3.11%
Dividend yield	0%
Shareholder yield	3.11%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	132.82%
10Y return CAGR	8.82%
10Y total return	132.82%
150-day SMA	$402.42
15Y price change	268.81%
15Y return CAGR	9.09%
15Y total return	268.81%
1D price change	0%
1M price change	3.95%
1M total return	3.95%
1W price change	4.22%
1W total return	4.22%
1Y price change	18.18%
1Y return CAGR	18.19%
1Y total return	18.18%
20-day SMA	$301.77
200-day SMA	$464.79
20Y price change	414.23%
20Y return CAGR	8.53%
20Y total return	414.23%
3M price change	22.67%
3M total return	22.67%
3Y price change	40.04%
3Y return CAGR	11.88%
3Y total return	40.04%
50-day SMA	$296.47
50-day SMA vs 200-day SMA	50under200
52-week high	$397.41
52-week high date	2026-10-28
52-week low	$244.54
52-week low date	2026-05-14
5Y price change	-48%
5Y return CAGR	-12.26%
5Y total return	-48%
6M price change	26.73%
6M total return	26.73%
All-time high	$818.60
All-time high date	2021-09-10
All-time low	$0.89
All-time low date	1982-08-20
Average true range (ATR)	$14.00
Average volume	395.8
Beta (5Y)	1.07
Change from 52-week high	-4.51%
Change from 52-week low	55.19%
Change from all-time high	-53.64%
Change from all-time low	42,593.22%
Change from open	-1.52%
Day's gap	1.54%
Dollar volume	$380
High price	$397.41
Low price	$385.34
Monthly RSI	59.59
Open price	$385.34
Position in 52-week range	0%
Previous close	$379.50
Price vs 150-day SMA	-5.7%
Price vs 20-day SMA	25.76%
Price vs 200-day SMA	-18.35%
Price vs 50-day SMA	28.01%
Relative volume	0
RSI	71.85
Sharpe ratio	0.37
Sharpe ratio (3Y)	0.93
Sharpe ratio (5Y)	0.75
Sortino ratio	0.6
Sortino ratio (3Y)	1.47
Sortino ratio (5Y)	1.24
Volume	1
Weekly RSI	51.78
YTD price change	22.14%
YTD total return	22.14%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	21.4M
Float percentage	79.85%
Shares change (QoQ)	-0.53%
Shares change (YoY)	-3.11%
Shares held by insiders	4.79%
Shares held by institutions	72.87%
Shares outstanding	26.7M
Short % of float	0%
Short % of shares	0%
Short ratio	1 days

Deeper analysis on BIO.B

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BIO.B report

Is a complete BIO.B research report available?

No complete published report is available for Bio-Rad Laboratories, Inc. (BIO.B) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Bio-Rad Laboratories, Inc. (BIO.B)

Price

Financial snapshot

Fair-value bridge

Latest news · BIO.B

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BIO.B indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BIO.B

Frequently asked questions